Suppr超能文献

成纤维细胞生长因子 23 与肾移植后心血管死亡率。

Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation.

机构信息

Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands;, †Department of Nephrology, UNIFESP, Sao Paolo, Brazil, ‡Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands.

出版信息

Clin J Am Soc Nephrol. 2013 Nov;8(11):1968-78. doi: 10.2215/CJN.01880213. Epub 2013 Aug 8.

Abstract

BACKGROUND AND OBJECTIVES

Circulating fibroblast growth factor 23 (FGF23) is associated with adverse cardiovascular outcomes in CKD. Whether FGF23 predicts cardiovascular mortality after kidney transplantation, independent of measures of mineral metabolism and cardiovascular risk factors, is unknown.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The association between plasma C-terminal FGF23 and cardiovascular mortality was analyzed in a single-center prospective cohort of 593 stable kidney transplant recipients (mean age ± SD, 52 ± 12 years; 54% male; estimated GFR, 47 ± 16 ml/min per 1.73 m(2)), at a median of 6.1 (interquartile range, 2.7-11.7) years after transplantation. Multivariate Cox regression models were built, adjusting for measures of renal function and mineral metabolism; Framingham risk factors; the left ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide (MR-proANP) and N-terminal-pro brain natriuretic peptide (NT-proBNP); and copeptin, the stable C-terminal portion of the precursor of vasopressin.

RESULTS

In multivariate linear regression analysis, MR-proANP (β=0.20, P<0.001), NT-proBNP (β=0.18, P<0.001), and copeptin (β=0.26, P<0.001) were independently associated with FGF23. During follow-up for 7.0 (interquartile range, 6.2-7.5) years, 128 patients (22%) died, of whom 66 (11%) died due to cardiovascular disease; 54 (9%) had graft failure. FGF23 was associated with an higher risk of cardiovascular mortality in a fully adjusted multivariate Cox regression model (hazard ratio [HR], 1.88 [95% confidence interval (CI), 1.11 to 3.19]; P=0.02). FGF23 was also independently associated with all-cause mortality (full model HR, 1.86 [95% CI, 1.27 to 2.73]; P=0.001). Net reclassification improved for both cardiovascular mortality (HR, 0.07 [95% CI, 0.01 to 0.14]; P<0.05) and all-cause mortality (HR, 0.11 [95% CI, 0.05 to 0.18]; P<0.001).

CONCLUSIONS

Plasma FGF23 is independently associated with cardiovascular and all-cause mortality after kidney transplantation. The association remained significant after adjustment for measures of mineral metabolism and cardiovascular risk factors.

摘要

背景与目的

循环成纤维细胞生长因子 23(FGF23)与 CKD 患者的不良心血管结局相关。FGF23 是否可预测肾移植后心血管死亡率,而不考虑矿物质代谢和心血管危险因素的评估,目前尚不清楚。

设计、地点、参与者和测量:在单中心前瞻性队列中,分析了 593 例稳定的肾移植受者(平均年龄±标准差,52±12 岁;54%为男性;估计肾小球滤过率[eGFR]为 47±16ml/min/1.73m²)的血浆 C 端 FGF23 与心血管死亡率之间的关系,这些患者在移植后中位时间 6.1(四分位间距,2.7~11.7)年后接受了研究。采用多变量 Cox 回归模型进行分析,校正肾功能和矿物质代谢的评估、Framingham 危险因素、前脑利钠肽中段片段(MR-proANP)和 N 端脑利钠肽前体(NT-proBNP)这两种左心室壁应变标志物以及加压素的稳定 C 末端部分 copeptin。

结果

多元线性回归分析显示,MR-proANP(β=0.20,P<0.001)、NT-proBNP(β=0.18,P<0.001)和 copeptin(β=0.26,P<0.001)与 FGF23 独立相关。在中位时间为 7.0(四分位间距,6.27.5)年的随访期间,有 128 例患者(22%)死亡,其中 66 例(11%)死于心血管疾病;54 例(9%)发生移植物失功。在完全校正的多变量 Cox 回归模型中,FGF23 与心血管死亡率升高相关(风险比[HR],1.88[95%置信区间(CI),1.113.19];P=0.02)。FGF23 还与全因死亡率独立相关(全模型 HR,1.86[95% CI,1.272.73];P=0.001)。两种模型的校正后重新分类均有改善,分别为心血管死亡率(HR,0.07[95% CI,0.010.14];P<0.05)和全因死亡率(HR,0.11[95% CI,0.05~0.18];P<0.001)。

结论

血浆 FGF23 与肾移植后心血管和全因死亡率独立相关。在调整矿物质代谢和心血管危险因素的评估后,该相关性仍然显著。

相似文献

引用本文的文献

9
Treatment Options for Anemia in Kidney Transplant Patients: A Review.肾移植患者贫血的治疗选择:综述
Kidney Med. 2023 May 27;5(8):100681. doi: 10.1016/j.xkme.2023.100681. eCollection 2023 Aug.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验